These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32067288)

  • 1. Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding.
    Meloni M; Puligheddu M; Carta M; Cannas A; Figorilli M; Defazio G
    Eur J Neurol; 2020 May; 27(5):779-786. PubMed ID: 32067288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.
    Meloni M; Puligheddu M; Sanna F; Cannas A; Farris R; Tronci E; Figorilli M; Defazio G; Carta M
    J Neurol Sci; 2020 Aug; 415():116869. PubMed ID: 32464351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease.
    Meloni M; Figorilli M; Carta M; Tamburrino L; Cannas A; Sanna F; Defazio G; Puligheddu M
    Sleep Breath; 2022 Sep; 26(3):1023-1031. PubMed ID: 34403081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
    Barone P; Santangelo G; Morgante L; Onofrj M; Meco G; Abbruzzese G; Bonuccelli U; Cossu G; Pezzoli G; Stanzione P; Lopiano L; Antonini A; Tinazzi M
    Eur J Neurol; 2015 Aug; 22(8):1184-91. PubMed ID: 25962410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-frequency repetitive transcranial magnetic stimulation over the primary foot motor area in Parkinson's disease.
    Maruo T; Hosomi K; Shimokawa T; Kishima H; Oshino S; Morris S; Kageyama Y; Yokoe M; Yoshimine T; Saitoh Y
    Brain Stimul; 2013 Nov; 6(6):884-91. PubMed ID: 23769414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
    Sano I; Taniguchi K
    Munch Med Wochenschr; 1972 Oct; 114(40):1717-9. PubMed ID: 4538893
    [No Abstract]   [Full Text] [Related]  

  • 8. The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study.
    Angst J; Woggon B; Schoepf J
    Arch Psychiatr Nervenkr (1970); 1977 Oct; 224(2):175-86. PubMed ID: 336002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
    Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
    Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
    Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
    Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apathy Profile in Parkinson's and Huntington's Disease: A Comparative Cross-Sectional Study.
    Sousa M; Moreira F; Jesus-Ribeiro J; Marques I; Cunha F; Canário N; Freire A; Januário C
    Eur Neurol; 2018; 79(1-2):13-20. PubMed ID: 29131091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
    Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
    BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
    Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson's disease.
    Varanese S; Perfetti B; Ghilardi MF; Di Rocco A
    PLoS One; 2011 Mar; 6(3):e17846. PubMed ID: 21437255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.
    Turner EH; Loftis JM; Blackwell AD
    Pharmacol Ther; 2006 Mar; 109(3):325-38. PubMed ID: 16023217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual Group Music Therapy for Apathy in Parkinson's Disease: A Pilot Study.
    Shah-Zamora D; Anderson S; Barton B; Fleisher JE
    J Geriatr Psychiatry Neurol; 2024 Jan; 37(1):49-60. PubMed ID: 37201184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study.
    Aliño JJ; Gutierrez JL; Iglesias ML
    Int Pharmacopsychiatry; 1976; 11(1):8-15. PubMed ID: 770365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the Geriatric Depression Scale measure depression in Parkinson's disease?
    Lopez FV; Split M; Filoteo JV; Litvan I; Moore RC; Pirogovsky-Turk E; Liu L; Lessig S; Schiehser DM
    Int J Geriatr Psychiatry; 2018 Dec; 33(12):1662-1670. PubMed ID: 30251374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of istradefylline on mood disorders in Parkinson's disease.
    Nagayama H; Kano O; Murakami H; Ono K; Hamada M; Toda T; Sengoku R; Shimo Y; Hattori N
    J Neurol Sci; 2019 Jan; 396():78-83. PubMed ID: 30423541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.